COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema (OPuS-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02670720
Recruitment Status : Terminated (preceding efficacy study of avoralstat in its current formulation was not significant and does not support continued development)
First Posted : February 2, 2016
Last Update Posted : February 17, 2016
Information provided by (Responsible Party):
BioCryst Pharmaceuticals

Brief Summary:
This is an open-label study designed to evaluate the long-term safety of prophylactic avoralstat (500 mg three times daily) when given to approximately 150 patients with hereditary angioedema (HAE) for a duration of up to 72 weeks. The study will also evaluate the long-term efficacy and impact on quality of life of avoralstat prophylactic treatment.

Condition or disease Intervention/treatment Phase
Hereditary Angioedema HAE Drug: avoralstat Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: OPuS-4: An Open-label Study to Evaluate the Long-term Safety of Avoralstat in Subjects With Hereditary Angioedema
Study Start Date : December 2015
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: avoralstat
Five avoralstat capsules (100 mg) to be taken three times daily by mouth
Drug: avoralstat
Other Name: BCX4161

Primary Outcome Measures :
  1. Proportion of subjects who discontinue due to a treatment-emergent adverse event, who experience a treatment-emergent serious AE, who experience a Grade 3 or 4 AE and who experience Grade 3 or 4 laboratory abnormalities [ Time Frame: Up to 72 weeks ]

Secondary Outcome Measures :
  1. Angioedema attack rate (subject-reported HAE attacks normalized for time on study) [ Time Frame: Up to 72 weeks ]
  2. Durability in response (assessed as subject-reported HAE attacks) [ Time Frame: change over time through 72 weeks ]
  3. Proportion of subjects who discontinue avoralstat with a reason of lack of efficacy [ Time Frame: Up to 72 weeks ]
  4. Quality of life as determined by the EQ-5D-5L [ Time Frame: Up to 72 weeks ]
  5. Quality of life as determined by the Angioedema Quality of Life Questionnaire [ Time Frame: Up to 72 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and non-pregnant, non-lactating females age ≥ 18 years.
  • Provide written, informed consent.
  • Prior completion of an avoralstat therapeutic study OR a confirmed diagnosis of HAE Type 1 or HAE Type 2.
  • Access to appropriate medication for the treatment of acute HAE attacks.
  • Adequate contraception.

Exclusion Criteria:

  • Females who are pregnant or breast feeding.
  • Clinically significant medical condition or medical history.
  • Abnormal screening ECG, laboratory or urinalysis finding that is clinically significant.
  • Investigational drug exposure within 30 days (except avoralstat).
  • History of or current alcohol or drug abuse.
  • HIV or active HBV or HCV infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02670720

Layout table for location information
Leuven, Belgium
Grenoble, France
Lille, France
Sponsors and Collaborators
BioCryst Pharmaceuticals
Layout table for investigator information
Principal Investigator: Henriette Farkas, MD, PhD, DSc Semmelweis University
Layout table for additonal information
Responsible Party: BioCryst Pharmaceuticals Identifier: NCT02670720    
Other Study ID Numbers: BCX4161-303
First Posted: February 2, 2016    Key Record Dates
Last Update Posted: February 17, 2016
Last Verified: February 2016
Keywords provided by BioCryst Pharmaceuticals:
hereditary angioedema
Additional relevant MeSH terms:
Layout table for MeSH terms
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn